樂觀
$150.52
情境價格
$271.040
+9.351 (+3.45%)收盤時
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.
IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.
BofA
$305
2026-10-09
BofA
2026-10-09
目標價
$305
Mizuho
$300
2026-10-07
Mizuho
2026-10-07
目標價
$300
Barclays
$300
2026-10-07
Barclays
2026-10-07
目標價
$300
UBS
$345
2026-09-30
UBS
2026-09-30
目標價
$345
RBC Capital
$319
2026-09-29
RBC Capital
2026-09-29
目標價
$319
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

IQVIA and Veeva Expand Partnership with New Standard Applications

IQVIA Launches Life Science Models to Predict Clinical Trial Outcomes

IQVIA Launches IQVIA Explorer™ to Enhance Commercial Decision-Making

IQVIA Prices $2 Billion Senior Notes Offering

IQVIA Launches AI-Powered Predictive Clinical Development Solution
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.
17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。